Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Pipeline
  • Remepy’s hybrid Parkinson’s therapy poised for phase 3
  • Pipeline

Remepy’s hybrid Parkinson’s therapy poised for phase 3

Pharmaphorum

Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.

Neuroscience

Read full story

pharminent May 20, 2026 (Last updated: May 21, 2026)

Pharmaphorum

Remepy’s Hybridopa therapy for Parkinson’s, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
Next: ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis

Related Stories

  • Pipeline

Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

pharminent June 5, 2026
  • Pipeline

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

pharminent May 21, 2026
  • Pipeline

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

pharminent May 20, 2026

You May Have Missed

  • M&A / Deals

Alzecure enters collaboration and with Lilly for Alzheimer’s project

pharminent June 9, 2026
  • Clinical Data

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

pharminent June 9, 2026
  • M&A / Deals

GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year

pharminent June 9, 2026
  • Regulatory

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval

pharminent June 9, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.